WO 2013/007698 A1 - Pharmaceutical Composition For Neurological Disorders - The Lens

Pharmaceutical Composition For Neurological Disorders

Published: Jan 17, 2013
Family: 5
Cited scholarly works: 193
Cited by: 2
Cites: 51
Additional Info: Cited Works Full text Published

Abstract

An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.

Claims

An anti-epileptic agent for use in the treatment of a neurological disorder other than
epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
An anti-epileptic agent according to Claim 1, wherein the daily dose is less than 2.5% of the minimum daily dose of the anti-epileptic agent which is effective for mood stabilisation or treatment of epileptic symptoms.
A pharmaceutical composition comprising a sub-therapeutic dose of an anti-epileptic agent as the sole active agent within the composition, together with a pharmaceutically acceptable carrier, diluent and/or excipient, wherein the sub-therapeutic dose is less than 20% of the minimum daily dose of the anti-epileptic agent which is effective for mood stabilisation or treatment of epileptic symptoms.
A pharmaceutical composition according to Claim 3, wherein the composition is for use in the treatment of a neurological disorder other than epilepsy.
A pharmaceutical composition according to Claim 3 or Claim 4, wherein the composition is adapted for transdermal administration.
A pharmaceutical composition according to Claim 5, wherein the transdermal administration is via the oral mucosa and the composition is in the form of powders, a capsule, a tablet, a lozenge, a troche or a pastille.
A pharmaceutical composition according to any of Claims 3 to 6, wherein the composition comprises a formulation which provides a controlled release or a sustained release of at least one active present in the composition.
A method of treating a neurological disorder other than epilepsy in a subject in need thereof, including the step of administering to the subject an anti-epileptic agent as the sole active agent, wherein the daily dose of the anti-epileptic agent is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
An agent, composition or method according to any preceding claim, wherein the anti- epileptic agent is selected from brivaracetam, carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam,
oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, safinamide, seletracetam, talampanel, tiagabine, topiramate, valproate, vigabatrin, zonisamide, benzodiazepines, barbiturates and sedative hypnotics.
A combination of:
(a) an anti-epileptic agent; and
(b) an active selected from a stimulant, an anti-Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor
for use in the treatment of a neurological disorder other than epilepsy characterised in that the daily dose of the anti-epileptic agent is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
A pharmaceutical composition comprising:
(a) A sub-therapeutic dose of an anti-epileptic agent;
(b) an active selected from a stimulant, an anti Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor; and
(c) a pharmaceutically acceptable carrier, diluent and/or excipient,
wherein the sub-therapeutic dose is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
A pharmaceutical composition according to Claim 11, wherein the composition is for use in the treatment of a neurological disorder other than epilepsy.
A pharmaceutical composition according to Claim 11 or Claim 12, wherein the composition is adapted for transdermal administration.
I l l
A pharmaceutical composition according to Claim 13, wherein the composition is adapted for administration via the oral mucosa and is in the form of powders, a capsule, a tablet, a lozenge, a troche or a pastille.
A pharmaceutical composition according to any of Claims 11 to 14, wherein the composition comprises a formulation which provides a controlled release or a sustained release of at least one active present in the composition.
A method of treating a neurological disorder other than epilepsy in a subject in need thereof, including the step of administering to the subject a combination of (a) an anti-epileptic agent, and (b) an active selected from a stimulant, an anti-Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor, wherein the daily dose of the anti-epileptic agent is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or the treatment of epileptic symptoms.
A combination, composition or method according to any of Claims 10 to 16, wherein the anti- epileptic agent is selected from brivaracetam, carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam,
oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, safinamide, seletracetam, talampanel, tiagabine, topiramate, valproate, vigabatrin, zonisamide, benzodiazepines, barbiturates and sedative hypnotics.
A combination, composition or method according to any of Claims 10 to 17, wherein the stimulant is selected from Adrafinil, Amantadine, Armodafinil, Carphedon, Modafinil, 4-
Fluoroamphetamine, 4-Fluoromethamphetamine, 4-Methylmethcathinone, 4-MTA, a-PPP,
Amphechloral, Amphetamine, Dextroamphetamine, Adderall, Amphetaminil,
Benzphetamine, Bupropion, Cathinone, Chlorphentermine, Clobenzorex, Clortermine,
Cypenamine, Diethylpropion, Dimethoxyamphetamine, Dimethylamphetamine,
Dimethylcathinone, Diphenyl prolinol, Ephedrine, Epinephrine, Ethcathinone,
Ethylamphetamine, Fencamfamine, Fenethylline, Fenfluramine, Fenproporex,
Feprosidnine, Furfenorex, Levomethamphetamine, Lisdexamfetamine, L-lysine-d- amphetamine, MDMA, Mefenorex, Methamphetamine, Methcathinone,
Methoxyphedrine, Methylone, Octopamine, Parahydroxyamphetamine, PMA, PMEA,
PMMA, PPAP, Phendimetrazine, Phenmetrazine, Phentermine, Phenylephrine,
Phenylpropanolamine, Prolintane, Propylamphetamine, Pseudoephedrine, Selegiline, Synephrine, Tenamphetamine, Xylopropamine; Piperazines, BZP, MeOPP, MBZP, mCPP, 2C-B-BZP, Tropanes, Brasofensine, CFT, Cocaethylene, Cocaine, Dimethocaine,
Lometopane, PIT, PTT, TI-121, Tesofensine, Troparil, WF-23, WF-33, Cholinergics, Arecoline, Cotinine, Convulsants, Bicuculline, Gabazine, Pentetrazol, Picrotoxin,
Strychnine, Thujone; Phenylaminooxazoles, 4-Methyl-aminorex, Aminorex, Clominorex, Fenozolone, Fluminorex, Pemoline, Thozalinone, Amineptine, Bemegride, BPAP,
Clenbuterol, Clofenciclan, Cyclopentamine, Cyprodenate, Desoxypipradrol,
Ethylphenidate, Ethamivan, Gilutensin, GYKI-52895, Hexacyclonate, Indanorex,
Indatraline, Isometheptene, Mazindol, MDPV, Mesocarb, methylphenidate,
Dexmethylphenidate, Naphthylisopropylamine, Nikethamide, Nocaine, Nomifensine, Phacetoperane, Phthalimidopropiophenone, Pipradrol, Prolintane, Propylhexedrine, Pyrovalerone, Tuamine, Vanoxerine, Yohimbine, Zylofuramine, Deanol,
Diethylaminoethanol, Dimefline Hydrochloride, Etilamfetamine Hydrochloride, Fencamfamin Hydrochloride, Fenetylline Hydrochloride, Fenfluramine Hydrochloride, Fenproporex Hydrochloride, Lobeline Hydrochloride, Pentetrazol, and Propylhexedrine.
A combination, composition or method according to any of Claims 10 to 18, wherein the anti- Parkinson's agent is selected from apomorphine, benserazide, benzatropine, bromocriptine, cabergoline, carbidopa, clozapine, domperidone, entacapone, levodopa, lisuride, orphenadrine, pergolide, piribedil, pramipexole, procyclidine, quetiapine, rasagiline, rivastigmine, ropinirole, rotigotine, selegiline, tolcapone, trihexyphenidyl, a dopamine agonist, a dopamine decarboxylase inhibitor, a catechol O methyl transferase (COMT) enzyme inhibitor, a monoamine oxidase-B inhibitor and an N-methyl-D-aspartate blocker.
A composition, composition or method according to any of Claims 10 to 19, wherein
acetylcholinesterase inhibitor is selected from tacrine, donepezil, galantamine and rivastigmine.